グライコミクスの世界市場：予測（2022年～2027年）

世界のグライコミクスの市場規模は、2020年に11億7,488万9,000米ドルとなり、2027年までに20億9,665万5,000米ドルに達し、8.63%のCAGRで成長すると予測されています。同市場は、主に世界の多くの地域でグライコミクスの研究活動が活発化していることから、注目すべきCAGRで推進されると予想されています。さらに、製薬会社による研究開発活動への収益性の高い投資も、予測期間中の市場成長の形成に重要な役割を果たすと考えられています。

当レポートでは、世界のグライコミクス市場について調査分析し、市場力学、市場分析、競合情報、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

• 市場概要
• COVID-19の影響
• 市場の定義
• 市場セグメンテーション

第2章 調査手法

• 調査データ
• 前提条件

第3章 エグゼクティブサマリー

• 調査のハイライト

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• ポーターのファイブフォース分析
  • エンドユーザーの交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 業界における競合情勢
• 業界バリューチェーン分析

第5章 グライコミクス市場分析：製品別

• イントロダクション
• 酵素
• 装置
• キット
• その他

第6章 グライコミクス市場分析：用途別

• イントロダクション
• 創薬
• 診断
• その他

第7章 グライコミクス市場分析：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • その他
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • 台湾
  • タイ
  • インドネシア
  • その他

第8章 競合環境と分析

• 主要企業と戦略分析
• 新興企業と市場の収益性
• 合併、買収、契約、およびコラボレーション
• ベンダーの競争力マトリックス

第9章 企業プロファイル

• Merck KGaA
• Thermo Fisher Scientific Inc.
• Takara Bio Inc.
• Shimadzu Corporation
• Agilent Technologies, Inc.
• New England Biolabs
• Asparia Glycomics
• Z Biotech, LLC.
• QA-Bio

The Glycomics Market is evaluated at US$1,174.889 million for the year 2020, growing at a CAGR of 8.63%, reaching the market size of US$2,096.655 million by the year 2027.

Glycomics is the comprehensive study of glycomes, including genetic, physiologic, pathological, and other aspects. It refers to the study of all the glycan structures of a given cell type or organism in a systematic manner. The global glycomics market is anticipated to propel at a noteworthy CAGR primarily attributable to the growing research activities in glycomics in many parts of the world. Additionally, the profitable investments by pharmaceutical companies in research and development activities also play a significant role in shaping the market growth over the forecast period. Moreover, increased government support for R&D in drug discovery and development coupled with the growth in proteomics research studies will bolster the demand for glycomics products shortly, thus positively impacting the growth over the next five years. Additionally, governments around the globe, particularly in developing economies, are further enabling academic researchers to expand their knowledge in the field and develop new tools and products to promote the field of glycoscience. This, in turn, augments the business growth opportunities for the market players shortly.

COVID-19 Impact

Biotechnology and pharmaceutical organizations are working together with government agencies to mitigate the COVID-19 pandemic by developing vaccines to planning for supply chain challenges in delivering those to the masses. Furthermore, commonly used drugs like hydroxychloroquine have significantly improved COVID-19 governance. Because many developed countries are running out of these drugs, their prominence has created a huge opportunity to develop COVID-19 governance drugs. Because of the high demand for COVID-19 vaccines and treatment drugs, the pharmaceutical and biotechnology industries and their research and development for new medications are expected to grow significantly. Because of these factors, COVID-19 had a significant positive impact on the Glycomic market. It is used for many research and development of drugs, especially in cases related to the diabetic population. The outbreak of the novel coronavirus disease is anticipated to have a significant impact on market growth since companies are striving hard to address the impact of this disease. Companies are expanding their R&D budgets and are working round the clock since the demand for commonly used drugs is significantly high in many countries. This, in turn, is boosting the pharmaceutical and biotechnology industry since the duration of this pandemic is still uncertain.

Key Developments in the market:

A significant volume of companies are working in the glycomics market; however, some have solidified their position as the leading providers in this industry. These players are involved in a plethora of investments, product launches, and R&D as a part of their growth strategies to strengthen their position further and provide better products and services to their customers worldwide, which is expected to propel the market's growth in the coming years. Some of these are:

In April 2022, GlycoNet, a leading global in glycomics research and drug development, has declared a $1.73 million investment in 13 glycomics projects across Canada. Health foundations, Industry partners, and business partners had also contributed US$5.97 million, bringing the total funding to $7.7 million. This fundraising will go toward research that will help patients with cancer, chronic diseases, infectious diseases, and neurodegenerative disorders live better lives.

In July 2020, GlycoNet, a Canadian network of excellence centred at UAlberta, received an investment worth US$16.3 million, enabling it to continue its mission to research glycomics to benefit human health.

In July 2020, GlycoNet awarded grant funding worth US$3.9 to 11 collaborative research projects, which will support a wide range of multidisciplinary research teams across 17 Canadian research projects to address their needs in numerous diseases such as cancer, and gastrointestinal inflammations, and cystic fibrosis, among others.

In May 2020, Pneumagen Ltd., a UK-based company engaged in treating infectious diseases by targeting the human glycome, announced that they raised £4 million, which was led by Chairman Bio (Thairm) with participation from the Scottish Investment Bank (SIB).

The glycomics market has been segmented based on product, application, and geography. Based on product, the market classification has been done into enzymes, instruments, kits, and others. The market has been segmented based on drug discovery, diagnostics, and others by application. Geographically, the market has been distributed in North America, South America, Europe, the Middle East and Africa, and the Asia Pacific.

Instruments to hold a significant market share.

By product, the instruments segment is expected to hold a significant share in the market throughout the next five years due to its vast and frequent applications in drug discovery and diagnostic testing. The enzymes segment will witness considerable growth during the forecast period due to their consumable nature. Moreover, the wide application of enzymes in numerous drug discovery procedures is one of the prime factors for the significant share of this segment in the glycomics market during the next five years. The kits segment is also projected to show robust growth during the next five years, which may be on account of their frequent usage.

Drug discovery to witness significant growth.

By application, the drug discovery segment is expected to propel at a healthy compound annual growth rate during the next five years. The extensive government support and increased focus of pharma companies, coupled with the growing prevalence of chronic diseases, are some of the key factors propelling the activities in the drug discovery segment by major pharmaceutical companies that play a crucial role in shaping the growth of this segment during the next five years.

North America to hold a considerable share.

Regionally, North America is anticipated to hold a considerable market share. The presence of major pharmaceutical and biopharmaceutical companies, including the region, and world-class infrastructure are some of the leading factors supporting the share of this segment during the next five years. Additionally, significant government support and factors such as high technology adoption are some of the additional factors for the high share of North America in the global market. However, the Asia Pacific region is anticipated to witness decent growth during the next five years because of the booming pharmaceutical and biopharmaceutical industries in countries like India and China.

Competitive Insights

The players in the glycomics market are implementing various growth strategies to gain a competitive advantage over their competitors in this market. Major market players have been covered along with their relative competitive strategies. The report also mentions recent deals and investments of different market players over the last few years. The company profiles section details the business overview, financial performance (public companies) for the past few years, key products and services being offered, and the recent deals and investments of these important players in the glycomics market.

Segmentation

By Product

• Enzymes
• Instruments
• Kits
• Others

By Application

• Drug Discovery
• Diagnostics
• Others

By Geography

• North America
  • USA
  • Canada
  • Mexico

• South America
  • Brazil
  • Argentina
  • Others

• Europe
  • Germany
  • France
  • UK
  • Others

• Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

Table of Contents

1. Introduction

• 1.1. Market Overview
• 1.2. COVID-19 Impact
• 1.3. Market Definition
• 1.4. Market Segmentation

2. Research Methodology

• 2.1. Research Data
• 2.2. Assumptions

3. Executive Summary

• 3.1. Research Highlights

4. Market Dynamics

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of End-Users
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. Glycomics Market Analysis, by Product

• 5.1. Introduction
• 5.2. Enzymes
• 5.3. Instruments
• 5.4. Kits
• 5.5. Others

6. Glycomics Market Analysis, by Application

• 6.1. Introduction
• 6.2. Drug Discovery
• 6.3. Diagnostics
• 6.4. Others

7. Glycomics Market Analysis, by Geography

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. UK
  • 7.4.4. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. India
  • 7.6.3. Japan
  • 7.6.4. South Korea
  • 7.6.5. Taiwan
  • 7.6.6. Thailand
  • 7.6.7. Indonesia 
  • 7.6.8. Others

8. Competitive Environment and Analysis

• 8.1. Major Players and Strategy Analysis
• 8.2. Emerging Players and Market Lucrativeness
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Vendor Competitiveness Matrix

9. Company Profiles 

• 9.1. Merck KGaA
• 9.2. Thermo Fisher Scientific Inc.
• 9.3. Takara Bio Inc.
• 9.4. Shimadzu Corporation
• 9.5. Agilent Technologies, Inc. 
• 9.6. New England Biolabs
• 9.7. Asparia Glycomics
• 9.8. Z Biotech, LLC.
• 9.9. QA-Bio